S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
The Day of Financial Reckoning Is Near (Ad)
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
The Day of Financial Reckoning Is Near (Ad)
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
The Day of Financial Reckoning Is Near (Ad)
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
The Day of Financial Reckoning Is Near (Ad)
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
The Financial Day of Reckoning Has Begun (Ad)
NASDAQ:MRKR

Marker Therapeutics - MRKR Stock Forecast, Price & News

$0.39
-0.05 (-11.27%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.38
$0.46
50-Day Range
$0.26
$0.56
52-Week Range
$0.25
$2.05
Volume
979,438 shs
Average Volume
4.93 million shs
Market Capitalization
$32.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.25

Marker Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
217.6% Upside
$1.25 Price Target
Short Interest
Healthy
3.14% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.75
Upright™ Environmental Score
News Sentiment
1.32mentions of Marker Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.42) to ($0.41) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.62 out of 5 stars

Medical Sector

139th out of 1,135 stocks

Pharmaceutical Preparations Industry

56th out of 557 stocks

MRKR stock logo

About Marker Therapeutics (NASDAQ:MRKR) Stock

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.

Marker Therapeutics Stock Performance

Shares of MRKR traded down $0.05 during mid-day trading on Friday, hitting $0.39. 979,438 shares of the company traded hands, compared to its average volume of 4,928,645. Marker Therapeutics has a 1-year low of $0.25 and a 1-year high of $2.05. The business has a 50 day moving average of $0.34 and a 200 day moving average of $0.39.

Marker Therapeutics (NASDAQ:MRKR - Get Rating) last posted its quarterly earnings data on Friday, May 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.01. The company had revenue of $0.96 million for the quarter. As a group, equities analysts anticipate that Marker Therapeutics will post -0.42 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Piper Sandler reduced their target price on shares of Marker Therapeutics from $3.50 to $1.50 in a report on Friday, May 27th.

Receive MRKR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Marker Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MRKR Stock News Headlines

Nasdaq Falls Over 100 Points, Marker Therapeutics Shares Spike Higher
See More Headlines
Receive MRKR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Marker Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MRKR Company Calendar

Last Earnings
11/10/2021
Today
8/14/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MRKR
Fax
N/A
Employees
56
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$1.25
High Stock Price Forecast
$1.50
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
+217.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$-41,880,000.00
Pretax Margin
-1,949.73%

Debt

Sales & Book Value

Annual Sales
$1.24 million
Book Value
$0.53 per share

Miscellaneous

Free Float
60,860,000
Market Cap
$32.90 million
Optionable
Optionable
Beta
1.28

Key Executives

  • Mr. Peter L. Hoang MBA (Age 50)
    Pres, CEO & Director
    Comp: $617.13k
  • Mr. Anthony H. Kim (Age 46)
    Chief Financial Officer
    Comp: $546.69k
  • Dr. Mythili Koneru M.D. (Age 44)
    Ph.D., Chief Medical Officer
    Comp: $550.14k
  • Dr. Juan F. Vera M.D. (Age 42)
    Co-Founder, COO, Chief Scientific Officer & Director
  • Mr. Michael J. Loiacono (Age 56)
    Chief Accounting Officer, Treasurer & Sec.
  • Ms. Elizabeth Donnelly
    Director of Admin.
  • Ms. Neda Safarzadeh
    VP/Head of Investor Relations, PR & Marketing
  • Mr. Edmund Cheung
    VP of HR
  • Dr. Nadia Agopyan Ph.D.
    Sr. VP of Regulatory Affairs
  • Dr. Robert Z. Florkiewicz Sr.
    Sr. Director of Molecular Biology & Virology













MRKR Stock - Frequently Asked Questions

Should I buy or sell Marker Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Marker Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" MRKR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRKR, but not buy additional shares or sell existing shares.
View MRKR analyst ratings
or view top-rated stocks.

What is Marker Therapeutics' stock price forecast for 2022?

1 Wall Street analysts have issued 1 year price targets for Marker Therapeutics' shares. Their MRKR share price forecasts range from $1.00 to $1.50. On average, they anticipate the company's stock price to reach $1.25 in the next year. This suggests a possible upside of 217.6% from the stock's current price.
View analysts price targets for MRKR
or view top-rated stocks among Wall Street analysts.

How have MRKR shares performed in 2022?

Marker Therapeutics' stock was trading at $0.95 at the beginning of the year. Since then, MRKR shares have decreased by 58.6% and is now trading at $0.3936.
View the best growth stocks for 2022 here
.

When is Marker Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our MRKR earnings forecast
.

How were Marker Therapeutics' earnings last quarter?

Marker Therapeutics, Inc. (NASDAQ:MRKR) announced its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.12) earnings per share for the quarter, beating analysts' consensus estimates of ($0.13) by $0.01.

What other stocks do shareholders of Marker Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Marker Therapeutics investors own include Amarin (AMRN), Viking Therapeutics (VKTX), PhaseBio Pharmaceuticals (PHAS), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Genocea Biosciences (GNCA), Strongbridge Biopharma (SBBP), Flexion Therapeutics (FLXN), Geron (GERN) and Ionis Pharmaceuticals (IONS).

What is Marker Therapeutics' stock symbol?

Marker Therapeutics trades on the NASDAQ under the ticker symbol "MRKR."

Who are Marker Therapeutics' major shareholders?

Marker Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.32%), Matrix Asset Advisors Inc. NY (0.30%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Frederick Gerald Wasserman, John Robert Wilson, Juan Vera, Paul Edward Walker and Peter L Hoang.
View institutional ownership trends
.

How do I buy shares of Marker Therapeutics?

Shares of MRKR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Marker Therapeutics' stock price today?

One share of MRKR stock can currently be purchased for approximately $0.39.

How much money does Marker Therapeutics make?

Marker Therapeutics (NASDAQ:MRKR) has a market capitalization of $32.90 million and generates $1.24 million in revenue each year. The company earns $-41,880,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis.

How can I contact Marker Therapeutics?

Marker Therapeutics' mailing address is 3200 Southwest Freeway Suite 2240, Houston TX, 77027. The official website for the company is www.markertherapeutics.com. The company can be reached via phone at (713) 400-6400 or via email at investor.relations@markertherapeutics.com.

This page (NASDAQ:MRKR) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.